FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer
The US Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) for the treatment of patients with metastatic HER2-positive breast cancer earlier today.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Herceptin